REG - Ovoca Bio PLC - Death of a Director

Ovoca BioAnnouncement

28/09/2020 07:05

RNS Number : 2165A
  
Ovoca Bio PLC
  
28 September 2020
  
 

Ovoca Bio plc
 
("Ovoca" or the "Company")
 
Death of a Director
 
Dublin, Ireland, 28 September, 2020 - Ovoca Bio announces with deep regret that Dr. Mikhail Mogutov, Executive Chairman of the Board, passed away suddenly on 24th September 2020.
 
Dr. Mikhail Mogutov joined the Board of Ovoca in June 2006 and was appointed Chairman of the Board in 2008. Kirill Golovanov, Chief Executive, will be stepping in as Interim Chairman of the Board.
 
Kirill Golovanov, Chief Executive of Ovoca Bio plc, said: "We are deeply saddened by the passing of Dr. Mikhail Mogutov. As Chairman Dr. Mogutov made many significant and impactful contributions to Ovoca Bio and will be greatly missed as a much respected colleague and friend. On behalf of the Board and everyone in the Ovoca Bio group, I extend our thoughts and deepest sympathy to all of Mikhail's family." 
 
 
End
 
For further information:


Ovoca Bio plc
Kirill Golovanov (Chief Executive)
Tel +353 1 661 9819
info@ovocabio.com
 
Davy (Nominated Adviser, Euronext Growth Advisor and Broker)
John Frain / Daragh O'Reilly
Tel: +353 1 679 6363
 
Consilium Strategic Communications
Chris Gardner, Chris Welsh, Carina Jurs
ovocabio@consilium-comms.com
Tel: +44 (0)20 3709 5700
 
About Ovoca Bio
Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire affecting an estimated ~4 million premenopausal women in the US alone.
 
The Company's lead product, BP-101, a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in Russia demonstrating statistically significant improvement in a number of key efficacy outcomes, including an increase in female sexual desire and reduction of symptoms of distress associated with HSDD.
 
Ovoca Bio is seeking to develop the drug for major global markets - in particular the United States and Europe, as well as obtain marketing approval in the Russian Federation.
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
BOAKKOBQPBKDPCB